



## Follicular Lymphoma and high-grade B-Cell Lymphoma

Learn how we successfully supported a large pharmaceutical company by rapidly collecting data for the HTA process of a hematology product.



# For an HTA process, we collected long-term follow-up data (>900 pts. up to 12 yrs.) in only 5 months

## Situation & challenges

- » The client's aim was to collect data supporting the HTA process and launch of a new drug in the relapsed/refractory setting
- » Follow-up data of patients with lymphoid neoplasms require long observation periods and high case numbers, thus few prospective data are available on patients with FL and DLBCL in higher treatment lines
- » The Tumor Registry Lymphatic Neoplasms (TLN) was launched in 2009 and has followed more than 3,750 patients, initially for 5 years.

## Our approach

- » Extension of TLN database, in two cohorts:
  1. Long-term follow-up of all patients with FL or DLBCL from the Tumor Registry Lymphatic Neoplasms (up to 12 years)
  2. Recruiting new patients with FL or DLBCL who start or have started their 3rd-line treatment between index date and data collection
- » Activation of our large and dedicated investigator network
- » Matching of populations to published trial data by MAIC analysis

## Results

- iOMEDICO delivered high-quality real world evidence for the client's HTA process on time
- With the TLN Registry we accelerated patient recruitment and generated long-term follow-up (up to 12 years) of specific hematological cohorts
- These real world data (RWD) were used as the external comparator of a pivotal study
- The project closed the gap between clinical trials and routine practice

## Project scope



Study type  
Registry




5 months  
time frame



150 sites  
in Germany



> 900  
patients



iOMEDICO has conducted various clinical projects (clinical trials, non-interventional studies, tumor registries) in the field of lymphoid neoplasms. Currently, eleven projects are ongoing. Our real world database includes >7,700 patients from more than 450 hospitals, medical practices, and comprehensive cancer centers.

Interested in working with us?

## Get in Touch

Contact us

E: [info@iomedico.com](mailto:info@iomedico.com)

W: [www.iomedico.com](http://www.iomedico.com)



## Together, we improve oncology

At iOMEDICO, we are experts and specialists in oncology and hematology clinical research. With over 28 years of experience and the power of our high-performance oncology network, we accelerate clinical trials, to bring new drugs and treatments to patients faster.

We conduct phase I-IV clinical trials as well as prospective tumor registries. With our large real world database, we provide comprehensive insights for planning drug development and science-driven trial design based on deep understanding of current patient care landscape. The platform links clinical data with translational analytics and patient reported outcome (PRO), to answer the complex questions of precision oncology – even for rare diseases.

IMPROVE  
ONCOLOGY